{"groups":[{"description":"FF-10501-01 tablets BID for 14 days of a 28 day cycle.\n\nFF-10501-01: FF-10501-01 will be administered orally BID on Days 1-14 of a 28-day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.","id":"FG000","title":"Phase 1 Cohort 1: 50mg/m2"},{"description":"FF-10501-01 tablets BID for 14 days of a 28-day cycle.\n\nFF-10501-01: FF-10501-01 will be administered orally BID on Days 1-14 of a 28-day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.","id":"FG001","title":"Phase 1 Cohort 2: 100mg/m2"},{"description":"FF-10501-01 tablets BID for 14 days of a 28-day cycle.\n\nFF-10501-01: FF-10501-01 will be administered orally BID on Days 1-14 of a 28-day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.","id":"FG002","title":"Phase 1 Cohort 3: 200mg/m2"},{"description":"FF-10501-01 tablets BID for 14 days of a 28-day cycle.\n\nFF-10501-01: FF-10501-01 will be administered orally BID on Days 1-14 of a 28-day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.","id":"FG003","title":"Phase 1 Cohort 4: 300mg/m2"},{"description":"FF-10501-01 tablets BID for 14 days of a 28-day cycle\n\nFF-10501-01: FF-10501-01 will be administered orally BID on Days 1-14 of a 28-day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.","id":"FG004","title":"Phase 1 Cohort 5: 400mg/m2"},{"description":"FF-10501-01 tablets BID every 14 days of a 28-day cycle\n\nFF-10501-01: FF-10501-01 will be administered orally BID on Days 1-14 of a 28-day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.","id":"FG005","title":"Phase 1 Cohort 6: 500mg/m2"},{"description":"FF-10501-01 tablets BID for 21 days of a 28 day cycle.\n\nFF-10501-01: FF-10501-01 will be administered orally BID on Days 1-21 of a 28-day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.","id":"FG006","title":"Phase 1 Cohort 7: 400mg/m2 in MDS/CMML"},{"description":"FF-10501-01 tablets BID for 28 days of a 28 day cycle.\n\nFF-10501-01: FF-10501-01 will be administered orally BID on Days 1-28 of a 28-day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.","id":"FG007","title":"Phase 1 Cohort 8: 400mg/m2"},{"description":"FF-10501-01 tablets BID for 21 days of a 28-day cycle\n\nFF-10501-01: FF-10501-01 will be administered orally on Days 1-21 of a 28-day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.","id":"FG008","title":"Phase 2a Cohort 9: 400mg/m2"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"7"},{"groupId":"FG005","numSubjects":"5"},{"groupId":"FG006","numSubjects":"5"},{"groupId":"FG007","numSubjects":"7"},{"groupId":"FG008","numSubjects":"17"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"7"},{"groupId":"FG005","numSubjects":"5"},{"groupId":"FG006","numSubjects":"5"},{"groupId":"FG007","numSubjects":"7"},{"groupId":"FG008","numSubjects":"17"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"2"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"6"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"7"},{"groupId":"FG005","numSubjects":"5"},{"groupId":"FG006","numSubjects":"3"},{"groupId":"FG007","numSubjects":"7"},{"groupId":"FG008","numSubjects":"11"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"For Phase 1, anticipated enrollment was 48 subjects; 38 subjects were enrolled and treated with FF-10501-01.\n\nFor Phase 2, anticipated enrollment was 20 subjects; 17 were enrolled and treated with FF-10501-01.","recruitmentDetails":"Participants were recruited based on physician referral at 2 academic medical centers between July 2014 and December 2018. The first participant was enrolled on August 21, 2014 and the last participant was enrolled on December 3, 2018. Study completion date was August 9, 2019."}